Woo H, Lee K, Park K, Kim D
Plants (Basel). 2024; 13(23).
PMID: 39683112
PMC: 11644518.
DOI: 10.3390/plants13233319.
van Vliet V, De Silva A, Mark B, Kikkert M
Virus Res. 2024; 344:199368.
PMID: 38588924
PMC: 11025011.
DOI: 10.1016/j.virusres.2024.199368.
Nemcovicova I, Lopusna K, Stibraniova I, Benedetti F, Berti F, Felluga F
J Enzyme Inhib Med Chem. 2024; 39(1):2301772.
PMID: 38221792
PMC: 10791089.
DOI: 10.1080/14756366.2024.2301772.
Gold I, Reis N, Glaser F, Glickman M
Semin Cell Dev Biol. 2022; 132:16-26.
PMID: 35764457
PMC: 9233553.
DOI: 10.1016/j.semcdb.2022.06.005.
Tan H, Hu Y, Jadhav P, Tan B, Wang J
J Med Chem. 2022; 65(11):7561-7580.
PMID: 35620927
PMC: 9159073.
DOI: 10.1021/acs.jmedchem.2c00303.
Docking Analysis of Some Bioactive Compounds from Traditional Plants against SARS-CoV-2 Target Proteins.
El-Aziz N, Khalifa I, Darwish A, Badr A, Aljumayi H, Hafez E
Molecules. 2022; 27(9).
PMID: 35566014
PMC: 9100219.
DOI: 10.3390/molecules27092662.
Aloin isoforms (A and B) selectively inhibits proteolytic and deubiquitinating activity of papain like protease (PLpro) of SARS-CoV-2 in vitro.
Lewis D, Ho J, Wills S, Kawall A, Sharma A, Chavada K
Sci Rep. 2022; 12(1):2145.
PMID: 35140265
PMC: 8828865.
DOI: 10.1038/s41598-022-06104-y.
Structure-Function Characteristics of SARS-CoV-2 Proteases and Their Potential Inhibitors from Microbial Sources.
Razali R, Asis H, Budiman C
Microorganisms. 2021; 9(12).
PMID: 34946083
PMC: 8706127.
DOI: 10.3390/microorganisms9122481.
SARS-CoV-2 Papain-Like Protease Potential Inhibitors-In Silico Quantitative Assessment.
Stasiulewicz A, Maksymiuk A, Nguyen M, Belza B, Sulkowska J
Int J Mol Sci. 2021; 22(8).
PMID: 33921228
PMC: 8069282.
DOI: 10.3390/ijms22083957.
Interactions between SARS coronavirus 2 papain-like protease and immune system: A potential drug target for the treatment of COVID-19.
Mahmoudvand S, Shokri S
Scand J Immunol. 2021; 94(4):e13044.
PMID: 33872387
PMC: 8250271.
DOI: 10.1111/sji.13044.
In search of drugs to alleviate suppression of the host's innate immune responses against SARS-CoV-2 using a molecular modeling approach.
Choudhury S, Moulick D, Borah A, Saikia P, Mazumder M
In Silico Pharmacol. 2021; 9(1):26.
PMID: 33842190
PMC: 8019474.
DOI: 10.1007/s40203-021-00085-y.
Spatial and temporal roles of SARS-CoV PL -A snapshot.
Yan S, Wu G
FASEB J. 2020; 35(1):e21197.
PMID: 33368679
PMC: 7883198.
DOI: 10.1096/fj.202002271.
Infections of the lung: a predictive, preventive and personalized perspective through the lens of evolution, the emergence of SARS-CoV-2 and its pathogenesis.
Ahluwalia P, Ahluwalia M, Vaibhav K, Mondal A, Sahajpal N, Islam S
EPMA J. 2020; 11(4):581-601.
PMID: 33204369
PMC: 7661834.
DOI: 10.1007/s13167-020-00230-1.
Identification of novel human USP2 inhibitor and its putative role in treatment of COVID-19 by inhibiting SARS-CoV-2 papain-like (PLpro) protease.
Mirza M, Ahmad S, Abdullah I, Froeyen M
Comput Biol Chem. 2020; 89:107376.
PMID: 32979815
PMC: 7487165.
DOI: 10.1016/j.compbiolchem.2020.107376.
Induction of the Antiviral Immune Response and Its Circumvention by Coronaviruses.
Liu P, Hong Y, Yang B, Shrestha P, Sajjad N, Chen J
Viruses. 2020; 12(9).
PMID: 32961897
PMC: 7551260.
DOI: 10.3390/v12091039.
Insights Into Dynamics of Inhibitor and Ubiquitin-Like Protein Binding in SARS-CoV-2 Papain-Like Protease.
Bosken Y, Cholko T, Lou Y, Wu K, Chang C
Front Mol Biosci. 2020; 7:174.
PMID: 32850963
PMC: 7417481.
DOI: 10.3389/fmolb.2020.00174.
Coronavirus in Continuous Flux: From SARS-CoV to SARS-CoV-2.
Dong Y, Dai T, Liu J, Zhang L, Zhou F
Adv Sci (Weinh). 2020; 7(20):2001474.
PMID: 32837848
PMC: 7361144.
DOI: 10.1002/advs.202001474.
Bioactive natural compounds against human coronaviruses: a review and perspective.
Xian Y, Zhang J, Bian Z, Zhou H, Zhang Z, Lin Z
Acta Pharm Sin B. 2020; 10(7):1163-1174.
PMID: 32834947
PMC: 7278644.
DOI: 10.1016/j.apsb.2020.06.002.
Viral Ubiquitin and Ubiquitin-Like Deconjugases-Swiss Army Knives for Infection.
Masucci M
Biomolecules. 2020; 10(8).
PMID: 32752270
PMC: 7464072.
DOI: 10.3390/biom10081137.
How ISG15 combats viral infection.
Freitas B, Scholte F, Bergeron E, Pegan S
Virus Res. 2020; 286:198036.
PMID: 32492472
PMC: 7483349.
DOI: 10.1016/j.virusres.2020.198036.